European Union regulators are expected to approve Abbott Laboratories (ABT) $33 billion acquisition of St. Jude Medical (STJ) , according to a Reuters report.

The commission is due to make a decision by Nov. 23. Neither company could be reached for comment Wednesday morning.

Both saw shares spike about 1.5% Tuesday, with Abbott hitting $39.81 per share and St. Jude reaching $79.75 per share.

Abbott Laboratories agreed to acquire St. Jude Medical Inc. for approximately $33 billion in cash, stock and debt back in April this year. The deal comprised of $46.75 in cash and 0.8708 shares, for a total consideration of approximately $85 per share of Abbott common stock, plus the total liabilities of St. Jude of approximately $9 billion will be assumed.

St. Jude has been facing criticism from Muddy Waters Capital since August, when the research firm wrote that its devices could be hacked by outsiders.

Separately, St. Jude announced on Oct. 11 that its implantable cardioverter defibrillator, or ICD, and its cardiac re-synchronization therapy devices made before May 23, 2015, could deposit lithium in patients as the battery depletes.

The company said only 0.21% of devices were affected, but advised doctors and patients to make sure they were aware of the battery life of its devices. At the time, analysts said the device failures likely wouldn't impact the deal.

Meanwhile Abbott is having legal struggles of its own, with its $7.9 billion acquisition of Alere (ALR) being stalled thanks to multiple lawsuits. The deal was announced in February.

However, Abbott attempted to withdraw its offer for Alere in April, despite a break up fee worth between $30 million and $50 million.

On Nov. 3 Abbott filed a breach of contract lawsuit against Alere.

"Abbott has reluctantly sought court intervention only after months of repeatedly and unsuccessfully attempting to get Alere to honor the agreement and provide information about business practices that are the focus of criminal and civil investigations that came to light after the merger agreement around federal anti-corruption, anti-kickback and U.S. healthcare laws," Abbott spokesperson Scott Stoffel wrote via email that day.

A hearing in that suit will be held Jan. 27.

More from Stocks

Video: Here's How Goldman Sachs May Change Under David Solomon

Video: Here's How Goldman Sachs May Change Under David Solomon

J&J Vows to Fight Verdict Linking Baby Powder to Ovarian Cancer

J&J Vows to Fight Verdict Linking Baby Powder to Ovarian Cancer

3 Reasons Why Netflix Bulls Are Getting Their Face Ripped Off After Earnings

3 Reasons Why Netflix Bulls Are Getting Their Face Ripped Off After Earnings

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony

Shark Tank Star Kevin O'Leary Reveals Why Stocks Haven't Corrected Recently

Shark Tank Star Kevin O'Leary Reveals Why Stocks Haven't Corrected Recently